The CGC empowers talented research groups to develop their ambitious and innovative scientific projects in a unique set up. The CGC interconnects the new research groups with the scientific, infrastructural and institutional strength of the Max Planck Institute of Molecular Physiology in Dortmund (MPI) and directly benefits from the developing Dortmund Science Hub and from the scientific expertise of the industrial partners.
The CGC was set up as a 5 years project. After two successful funding periods (CGCI: 2005-2010; CGCII: 2012-2017) a third funding period of the CGC (CGCIII) was established in October 2018 as a partnership between the MPG and MPI, and the companies AstraZeneca, Merck KGaA and Pfizer. The CGCIII supports 4 newly-established independent research groups led by Malte Gersch, Jochen Imig, Peter ‘t Hart and Peng Wu.